Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Executive Summary
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
You may also be interested in...
Employee’s Decoy Laptop Did Not Trick Pfizer Security, Trade Secret Suit Says
Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.
180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.